Mentions19
Posts6
Latest post3 Sept 2026
Relay Therapeutics, Inc.Molecular Glue Degraders: Moving from Serendipity to Rational Design-3 Sept 2026
Monte Rosa Therapeutics, Inc.Molecular Glue Degraders: Moving from Serendipity to Rational Design-3 Sept 2026
Foghorn Therapeutics Inc.Molecular Glue Degraders: Moving from Serendipity to Rational Design-3 Sept 2026
Arvinas, Inc.Molecular Glue Degraders: Moving from Serendipity to Rational Design-3 Sept 2026
Protagonist Therapeutics, Inc.Molecular Glue Degraders: Moving from Serendipity to Rational Design-3 Sept 2026
Kymera Therapeutics, Inc.Molecular Glue Degraders: Moving from Serendipity to Rational Design-3 Sept 2026
PMV Pharmaceuticals, Inc.PMV Pharma: Making p53 Druggable? $pmvp-20 Aug 2026
Nurix Therapeutics, Inc.Brain-penetrant PROTACs: Arvinas & Nurix Therapeutics $arvn, $nrix-9 Jul 2026
Arvinas, Inc.Brain-penetrant PROTACs: Arvinas & Nurix Therapeutics $arvn, $nrix-9 Jul 2026
Arvinas, Inc.PROTACs: Protein Degradation for 'Undruggable' Targets-9 Jun 2026
Kymera Therapeutics, Inc.PROTACs: Protein Degradation for 'Undruggable' Targets-9 Jun 2026
Revolution Medicines, Inc.Chemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
Relay Therapeutics, Inc.Chemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
Novartis AGChemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
AbbVie Inc.Chemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
AstraZeneca PLCChemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
Bayer AktiengesellschaftChemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
Eli Lilly and CompanyChemoproteomics: Scorpion/Antares, Vividion Tx, Frontier Medicines-14 May 2026
Enliven Therapeutics, Inc.Terns Pharma: Derisked Allosteric Inhibitors $tern-8 Apr 2026